AQST Q4 2023 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$13M+23.6% YoY

Gross Profit

$9M64.6% margin

Operating Income

-$4M-29.6% margin

Net Income

-$8M-61.4% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+1.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$940,000

Balance Sheet

Total Assets

$57M

Total Liabilities

$164M

Stockholders' Equity

-$106M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$13M	$11M	+23.6%
Gross Profit	$9M	$5M	+58.6%
Operating Income	-$4M	-$11M	+63.5%
Net Income	-$8M	-$12M	+34.3%

Revenue Segments

Manufacture and Supply Revenue

$11M83%

License and Royalty Revenue

$2M14%

Co-Development and Research Fees

$335,0003%

Geographic Segments

UNITED STATES

$12M89%

Non-US

$1M11%